Keywords
prediabetic state
primary prevention
FINDRISC
early diagnosis
hyperglycemia
chronic disease
How to Cite
Abstract
Background: Type II diabetes (T2D) is a chronic disease with high rates of morbidity and mortality, which implies a great impact on the economy and health systems due to its high prevalence rates, complications, and costs. Prediabetes arises as an abnormal state that precedes type II diabetes and is associated with multiple risk factors. Therefore, strategies such as the FINDRISC survey have emerged to identify people at risk of developing prediabetes and type II diabetes as early as possible.
Objective: The objective of this study is to identify individuals with a high risk of developing type II diabetes and prediabetes using the FINDRISC scale in a cohort of adults in Cundinamarca, Colombia.
Methodology: Descriptive observational cross-sectional study developed in 3257 people over 18 years of age without a previous diagnosis of type II diabetes. Results are presented in absolute frequency measures and percentages. FINDRISC variables included age, body mass index (BMI), waist circumference (WC), diet, physical activity, history of hypertension, history of hyperglycemia, and family history of type II diabetes.
Results: Of the total respondents, 48% had at least a moderate risk of developing type II diabetes within the following 10 years (FINDRISC >=12). It was observed that a large number of subjects were not meeting goals for modifiable risk factors evaluated by the scale, such as physical activity (69%), diet (60%), and body mass index (70%). The family history of diabetes mellitus was a positive factor in more than half of the respondents.
Conclusion: The FINDRISC scale may allow us to reduce the high rates of morbidity and mortality, associated complications, and high rates of people undiagnosed with these conditions. The results emphasize the importance of habits and lifestyle in the population at risk for diabetes and prediabetes.
References
Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576(2019):51-60. https://doi.org/10.1038/s41586-019-1797-8
Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: A pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077-2093. https://doi.org/10.1016/S0140-6736(24)02317-1
Asociación Latinoamericana de Diabetes (ALAD). Guías ALAD sobre el diagnóstico, control y tratamiento de la diabetes mellitus tipo 2 con medicina basada en evidencia [Internet]. Ed. 2019. [cited 2024]. Available at: https://www.revistaalad.com/guias/5600AX191_guias_alad_2019.pdf
Jiménez Forero LA. Día mundial de la diabetes 2024. [Internet]. Bogotá: Cuenta de Alto Costo; 2024 [cited 2024]. Available at: https://cuentadealtocosto.org/general/dia-mundial-de-la-diabetes/.
Dagenais GR, Gerstein HC, Zhang X, McQueen M, Lear S, Lopez-Jaramillo P, et al. Variations in diabetes prevalence in low-, middle- and high-income countries: Results of the prospective urban and rural epidemiological study. Diabetes Care. 2016;39(5):780–787. https://doi.org/10.2337/dc15-2338
Friege F, Lara Esqueda A, Suverza A, Campuzano R, Vanegas E, Vidrio M, et al. Consenso de Prediabetes. Documento de posición de la Asociación Latinoamericana de Diabetes (ALAD). Consensos ALAD. 2009;XVII(4):146-158.
Golfetto S, Núñez O, Peña M, Uzcategui K, Vaamonde Y, Golfetto I, et al. Riesgo de desarrollar diabetes tipo 2 según LA FINDRISC y enfermedad arterial periférica. Rev Digit Postgrad. 2020;9(2). https://doi.org/10.37910/RDP.2020.9.2.e208
Ministerio de Salud y Protección Social de Colombia. Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años [Internet]. Bogotá: Ministerio de Salud y Protección Social; 2016 [cited 2024]. Available at: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/gpc-completa-diabetes-mellitus-tipo2-poblacion-mayor-18-anos.pdf
de Cocker J. Validation of the Finnish diabetes risk score (FINDRISC) for diabetes screening in the Belgian population [Internet]. Ugent.be. [cited 2024]. Available in: https://libstore.ugent.be/fulltxt/RUG01/002/304/550/RUG01-002304550_2016_0001_AC.pdf.
Soriguer F, Valdés S, Tapia MJ, Esteva I, Ruiz de Adana MS, Almaraz MC, et al. Validation of FINDRISC (FINnish Diabetes Risk SCore) for the prediction of type 2 diabetes risk in a population from southern Spain. Slate Studio. Med Clin (Barc). 2012;138(9):371-376. https://doi.org/10.1016/j.medcli.2011.05.025
Lindström J, Tuomilehto J. The diabetes risk score: A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003 Mar;26(3):725-731. https://doi.org/10.2337/diacare.26.3.725
De Los Angeles R, Bolaños R, Myriam L, Shigematsu R, Jiménez Ruíz JA, Juárez Márquez SA, et al. Direct health care costs in subjects with type 2 diabetes mellitus in Mexico: Microcosting analysis. Rev Panam Salud Publica. 2010;28(6):412-420.
González A, Avilés P, Raúl E, Rosas P, Toro Bellot F, Giles OA, et al. FINDRISC FINnish diabetes risk score questionnaire for the detection of undiagnosed diabetes and prediabetes. Arch Med Fam. 2018;20(1):5-13.
Mariano Cantillo HJ, Ocampo DF, Cuello Santana KL. Use of the FINDRISK instrument to identify the risk of prediabetes and type 2 diabetes mellitus. Repert Med Cir. 2019;28(3):157-163. https://doi.org/10.31260/RepertMedCir.v28.n3.2019.956
Bohórquez Moreno CE, Barreto Vasquez M, Muvdi Muvdi YP, Rodríguez Sanjuán A, Badillo Viloria MA, Martínez de la Rosa WA, et al. Factores modificables y riesgo de diabetes mellitus tipo 2 en adultos jóvenes: un estudio transversal. Cienc Enferm. 2020;26:14. https://doi.org/10.29393/CE26-7FMCB70007
Rodriguez M, Mendoza MD. Risk factors of type 2 diabetes mellitus in adult population. Barranquilla, Colombia. Rev Colomb Endocrinol Diabet Metab. 2019;6(2):86-91. https://doi.org/10.53853/encr.6.2.482
Ligorria S, Guzman N. Estimación del riesgo de desarrollar diabetes mellitus 2 en el recurso humano del hospital misericordia a través del test de FINDRISC [Internet]. Química Clínica [cited 2024]. Available at: https://cobico.com.ar/wp-content/archivos/2019/11/riesgo-de-diabetes.pdf
Cajamarca Naula RS, Cajamarca Naula KJ, Espadero Faican RG, Guapacasa Yanza AB. Uso del instrumento FINDRISC para identificar riesgo de prediabetes y diabetes mellitus de tipo 2 en la parroquia de Honorato Vásquez-Cañar. Ciencia Latina. 2022;6(3):4077-4093. https://doi.org/10.37811/cl_rcm.v6i3.2521
López-Balderas N, González-Jiménez B, Torres R, Rosas FP, López Ramos ED, Torres-Hernández RM. Correlación del Finnish Diabetes Risk Score y la hemoglobina glucosilada en la identificación de diabetes y prediabetes en docentes universitarios de ciencias de la salud. Cienc Innov Salud. 2021;e137:289-297. http://dx.doi.org/10.17081/innosa.138
Rodolfo Lahsen, M. Metabolic syndrome and diabetes. Rev Med Clin Las Condes. 2014;25(1):47-52. https://doi.org/10.1016/S0716-8640(14)70010-0
Ozsoy S, Sultanoglu N, Sanlidag T. The role of Mediterranean diet and gut microbiota in type-2 diabetes mellitus associated with obesity (diabesity). J Prev Med Hyg. 2022;63(2 Suppl 3):e87-E92. https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2751
Sánchez-Quintero MJ, Delgado J, Medina-Vera D, Becerra-Muñoz VM, Queipo-Ortuño MI, Estévez M, et al. Beneficial effects of essential oils from the mediterranean diet on gut microbiota and their metabolites in ischemic heart disease and type-2 diabetes mellitus. Nutrients. 2022;14(21):4650. https://doi.org/10.3390/nu14214650
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Revista Colombiana de Endocrinología, Diabetes & Metabolismo